Trinity Biotech surges 34.53% amid market decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 12 2024
0mins
Trinity Biotech PLC's stock has surged by 34.53% in pre-market trading, crossing above its 5-day SMA. This significant price movement occurs in the context of a slight decline in the broader market, with the Nasdaq-100 and S&P 500 both down 0.04%.
The surge is attributed to sector rotation, as investors are shifting their focus towards biotechnology stocks despite the overall market weakness. This trend indicates a growing interest in companies like Trinity Biotech, which may be benefiting from specific investor sentiment or recent developments in the biotech sector.
This price increase could signal a positive outlook for Trinity Biotech, suggesting that investors are optimistic about the company's future prospects, especially in a challenging market environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRIB
About TRIB
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trinity Biotech Reports Q1 2026 Earnings with Revenue Growth
- Significant Loss Reduction: Trinity Biotech reported a net loss of $4.39 million for Q1 2026, translating to a loss of $0.23 per share, which is a 50% decrease from last year's loss of $8.79 million or $0.48 per share, indicating progress in cost management.
- Strong Revenue Growth: Total revenue for the first quarter reached $10.85 million, a 43% increase year-over-year, primarily driven by a surge in sales of Rapid HIV tests, which rose from $0.4 million last year to $3.7 million, reflecting a significant uptick in market demand.
- Improved EBITDA: The EBITDA loss for this quarter was $1.95 million, considerably lower than the $5.84 million loss reported last year, while adjusted EBITDA showed a loss of $1.06 million, demonstrating enhanced operational efficiency.
- Positive Future Outlook: The company anticipates completing over 2 million orders for its TrinScreen HIV tests in Q3 2026 and plans to scale up UniGold HIV commercially during the same quarter, aiming to improve gross margins and cash flow as part of its Comprehensive Transformation Plan.
See More
Trinity Biotech Reports Q1 Financial Results with Improved Losses
- Reduced Net Loss: Trinity Biotech reported a net loss of $4.4 million in Q1 2026, halving the loss from $8.8 million in Q1 2025, indicating improved financial management and operational efficiency.
- Significant Revenue Growth: The company achieved revenue of $10.8 million in Q1, representing a 42.1% year-over-year increase, reflecting strong market demand and enhanced product sales, which bolsters future profitability potential.
- Improved Adjusted EBITDA: The adjusted EBITDA for Q1 2026 was negative $1.1 million, a significant improvement from negative $4.0 million in Q1 2025, showcasing progress in operational efficiency and cost management.
- Positive Financial Signals: Although still in a loss position, the improvements in net loss and EBITDA provide positive signals for investors, indicating that the company is making strides towards profitability, potentially attracting more investor interest.
See More
Trinity Biotech Reports Q1 2026 Financial Results with Strong Demand for HIV Tests
- Strong Orders: Trinity Biotech has secured additional purchase orders for over 2 million units of its TrinScreen™ HIV rapid test, scheduled for fulfillment in Q3 2026, which is expected to significantly contribute to the company's revenue and profitability targets for 2026, reflecting robust demand for rapid HIV diagnostics in global health markets.
- Improved Financial Performance: The company reported a 43% year-on-year revenue increase to $10.8 million in Q1 2026, primarily driven by a substantial rise in rapid HIV sales, particularly TrinScreen™ HIV, which surged from $0.4 million in Q1 2025 to $2.3 million, indicating enhanced market acceptance of its products.
- Margin Enhancement: Gross margin improved from 25.2% to 35.4%, supported by operational restructuring under the Comprehensive Transformation Plan, with gross profit reaching $3.8 million compared to $1.9 million in Q1 2025, demonstrating significant progress in cost control and operational efficiency.
- Strategic Transformation Plan: The ongoing Comprehensive Transformation Plan includes the outsourcing of UniGold HIV™ production, expected to be scaled up by Q3 2026, which will further enhance the company's EBITDA and cash flow generation capabilities, supporting its long-term growth strategy.
See More
Trinity Biotech Reports FY 2025 Financial Results
- Revenue Decline: Trinity Biotech reported FY 2025 revenue of $43.8 million, a 28.9% year-over-year decrease, indicating significant sales challenges amid intensified market competition and weak product demand, which may impact future liquidity.
- Increased Net Loss: The company recorded a net loss of $37.4 million, up from $31.8 million in 2024, which included a one-off IFRS charge of $10 million related to modifications in Perceptive financing arrangements, highlighting financial management pressures.
- Adjusted EBITDA Improvement: The adjusted EBITDA for 2025 was negative $5.9 million, an improvement from negative $11.3 million in 2024, suggesting some progress in cost control despite the overall financial situation remaining challenging.
- Financing Agreement Signed: Trinity Biotech entered into a $25 million standby equity purchase agreement with investors to strengthen its capital structure and provide operational funding, reflecting proactive measures in seeking financial stability.
See More
Trinity Biotech Appoints New Head of North America Operations
- Executive Appointment: Trinity Biotech has appointed Jerry Lydon as Head of North America Commercial Operations, aiming to enhance revenue growth and profitability in its core diagnostics business, reflecting ongoing progress in the company's Comprehensive Transformation Plan.
- Product Upgrade: The Premier HbA1c 9210™ platform has received the prestigious
See More
Trinity Biotech Announces Positive Results for Enhanced Prostate Cancer Test
- Clinical Study Results: Trinity Biotech's EpiCapture prostate cancer test was evaluated in approximately 750 patient samples, demonstrating a clinical accuracy of 85%, indicating strong clinical utility in oncology diagnostics that can aid physicians in making more precise clinical decisions.
- Significant Market Potential: With U.S. national expenditures for prostate cancer care exceeding $20 billion annually, the launch of EpiCapture positions Trinity Biotech to enter the precision oncology diagnostics market, addressing growing market demand and driving future revenue growth for the company.
- Non-Invasive Testing Advantage: EpiCapture, as a urine liquid biopsy test, offers a simpler and non-invasive method for assessing high-grade prostate cancer risk compared to high-resolution MRI scans and needle biopsies, potentially attracting more patients to opt for this testing.
- Future Commercialization Plans: Trinity plans to commercialize EpiCapture as a proprietary Laboratory Developed Test (LDT) through a New York State Department of Health-certified diagnostic reference laboratory, which will expedite the rollout of precision oncology testing services across the U.S.
See More
Trinity Biotech Reports Q1 2026 Earnings with Revenue Growth
- Significant Loss Reduction: Trinity Biotech reported a net loss of $4.39 million for Q1 2026, translating to a loss of $0.23 per share, which is a 50% decrease from last year's loss of $8.79 million or $0.48 per share, indicating progress in cost management.
- Strong Revenue Growth: Total revenue for the first quarter reached $10.85 million, a 43% increase year-over-year, primarily driven by a surge in sales of Rapid HIV tests, which rose from $0.4 million last year to $3.7 million, reflecting a significant uptick in market demand.
- Improved EBITDA: The EBITDA loss for this quarter was $1.95 million, considerably lower than the $5.84 million loss reported last year, while adjusted EBITDA showed a loss of $1.06 million, demonstrating enhanced operational efficiency.
- Positive Future Outlook: The company anticipates completing over 2 million orders for its TrinScreen HIV tests in Q3 2026 and plans to scale up UniGold HIV commercially during the same quarter, aiming to improve gross margins and cash flow as part of its Comprehensive Transformation Plan.
See More
Trinity Biotech Reports Q1 Financial Results with Improved Losses
- Reduced Net Loss: Trinity Biotech reported a net loss of $4.4 million in Q1 2026, halving the loss from $8.8 million in Q1 2025, indicating improved financial management and operational efficiency.
- Significant Revenue Growth: The company achieved revenue of $10.8 million in Q1, representing a 42.1% year-over-year increase, reflecting strong market demand and enhanced product sales, which bolsters future profitability potential.
- Improved Adjusted EBITDA: The adjusted EBITDA for Q1 2026 was negative $1.1 million, a significant improvement from negative $4.0 million in Q1 2025, showcasing progress in operational efficiency and cost management.
- Positive Financial Signals: Although still in a loss position, the improvements in net loss and EBITDA provide positive signals for investors, indicating that the company is making strides towards profitability, potentially attracting more investor interest.
See More
Trinity Biotech Reports Q1 2026 Financial Results with Strong Demand for HIV Tests
- Strong Orders: Trinity Biotech has secured additional purchase orders for over 2 million units of its TrinScreen™ HIV rapid test, scheduled for fulfillment in Q3 2026, which is expected to significantly contribute to the company's revenue and profitability targets for 2026, reflecting robust demand for rapid HIV diagnostics in global health markets.
- Improved Financial Performance: The company reported a 43% year-on-year revenue increase to $10.8 million in Q1 2026, primarily driven by a substantial rise in rapid HIV sales, particularly TrinScreen™ HIV, which surged from $0.4 million in Q1 2025 to $2.3 million, indicating enhanced market acceptance of its products.
- Margin Enhancement: Gross margin improved from 25.2% to 35.4%, supported by operational restructuring under the Comprehensive Transformation Plan, with gross profit reaching $3.8 million compared to $1.9 million in Q1 2025, demonstrating significant progress in cost control and operational efficiency.
- Strategic Transformation Plan: The ongoing Comprehensive Transformation Plan includes the outsourcing of UniGold HIV™ production, expected to be scaled up by Q3 2026, which will further enhance the company's EBITDA and cash flow generation capabilities, supporting its long-term growth strategy.
See More
Trinity Biotech Reports FY 2025 Financial Results
- Revenue Decline: Trinity Biotech reported FY 2025 revenue of $43.8 million, a 28.9% year-over-year decrease, indicating significant sales challenges amid intensified market competition and weak product demand, which may impact future liquidity.
- Increased Net Loss: The company recorded a net loss of $37.4 million, up from $31.8 million in 2024, which included a one-off IFRS charge of $10 million related to modifications in Perceptive financing arrangements, highlighting financial management pressures.
- Adjusted EBITDA Improvement: The adjusted EBITDA for 2025 was negative $5.9 million, an improvement from negative $11.3 million in 2024, suggesting some progress in cost control despite the overall financial situation remaining challenging.
- Financing Agreement Signed: Trinity Biotech entered into a $25 million standby equity purchase agreement with investors to strengthen its capital structure and provide operational funding, reflecting proactive measures in seeking financial stability.
See More
Trinity Biotech Appoints New Head of North America Operations
- Executive Appointment: Trinity Biotech has appointed Jerry Lydon as Head of North America Commercial Operations, aiming to enhance revenue growth and profitability in its core diagnostics business, reflecting ongoing progress in the company's Comprehensive Transformation Plan.
- Product Upgrade: The Premier HbA1c 9210™ platform has received the prestigious
See More
Trinity Biotech Announces Positive Results for Enhanced Prostate Cancer Test
- Clinical Study Results: Trinity Biotech's EpiCapture prostate cancer test was evaluated in approximately 750 patient samples, demonstrating a clinical accuracy of 85%, indicating strong clinical utility in oncology diagnostics that can aid physicians in making more precise clinical decisions.
- Significant Market Potential: With U.S. national expenditures for prostate cancer care exceeding $20 billion annually, the launch of EpiCapture positions Trinity Biotech to enter the precision oncology diagnostics market, addressing growing market demand and driving future revenue growth for the company.
- Non-Invasive Testing Advantage: EpiCapture, as a urine liquid biopsy test, offers a simpler and non-invasive method for assessing high-grade prostate cancer risk compared to high-resolution MRI scans and needle biopsies, potentially attracting more patients to opt for this testing.
- Future Commercialization Plans: Trinity plans to commercialize EpiCapture as a proprietary Laboratory Developed Test (LDT) through a New York State Department of Health-certified diagnostic reference laboratory, which will expedite the rollout of precision oncology testing services across the U.S.
See More
